Clinical trials · Chicago, IL
Liver Diseases clinical trials in Chicago
We’re tracking 21 recruiting liver diseases studies with a site in or near Chicago — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Chicago, IllinoisAges 18 years+ - NCT05919680RecruitingPhase 2
NST-6179 for liver disease from intestinal failure in adults
This Phase 2 study tests NST-6179 in people who have intestinal failure–associated liver disease (IFALD). It aims to improve liver function and overall outcomes for people whose liver inflammation and lab tests have been abnormal for at least 6 months.
Chicago, IllinoisAges 16 years+ - NCT05733832Recruiting
Transitional care after hospital discharge for serious liver disease
This trial tests an extra support program after you leave the hospital to help people with advanced liver disease avoid complications and stay on track. It may help by providing structured follow-up soon after discharge.
Chicago, IllinoisAges 18 years+ - NCT04613921Recruiting
Liver transplant study for severe worsening liver failure
This study looks at when liver transplant is offered and what outcomes happen in people with cirrhosis who have severe “acute-on-chronic” worsening. It may help doctors decide which patients benefit most from transplant and improve care after listing or not listing.
Chicago, IllinoisAges 18–80 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Chicago, IllinoisAges 18–80 - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT07165028RecruitingPhase 3
Study of new drugs for fatty liver with scarring
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Chicago, IllinoisAges 18 years+ - NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Chicago, IllinoisAges 2–25 - NCT05744713Enrolling by invitation
Study of adults with long-term liver disease using health records
This observational study looks at adults with chronic liver disease (including cirrhosis) to better understand how people are managed and how they feel over time. Because it does not change your treatment, it may help researchers improve care and patient support.
Chicago, IllinoisAges 18 years+ - NCT06871111RecruitingPhase 1
Bacteria treatment study for liver disease patients
This trial tests whether giving a mixture of helpful bacteria can improve gut health in people hospitalized with serious liver problems. It aims to see if restoring these bacteria can help with recovery.
Chicago, IllinoisAges 18 years+ - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Chicago, IllinoisAges 18 years+ - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
Chicago, IllinoisAges 3–13 - NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Chicago, IllinoisAges 1 day–17 years - NCT03228290Recruiting
Liver transplant care study using patient function check
This study looks at how people with liver disease function day to day, especially around liver transplant care. It may help improve how doctors assess readiness and recovery needs.
Chicago, IllinoisAges 18 years+ - NCT01644903Recruiting
Checking biomarkers after a liver transplant
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Chicago, IllinoisAges 18 years+ - NCT06355310RecruitingPhase 2
Studying an SGLT2 inhibitor for fatty liver in teens
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
Chicago, IllinoisAges 16–20 - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Chicago, IllinoisAges 18 years+ - NCT03803423Recruiting
Using social media to find kidney or liver donors
This study tests a way to spread information on how to register as a live organ donor using social media. You may be contacted to help identify potential live kidney or liver donors, if you fit the study’s basic requirements.
Chicago, IllinoisAges 18 years+ - NCT05264051Recruiting
MRI scan to predict outcomes in liver disease
This study looks at MRI images taken as part of routine care to see if they can help predict future health problems in people with liver disease. If you already have an MRI scheduled for clinical reasons, this may help doctors better estimate risk over time.
Chicago, IllinoisAges 18 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Hammond, IndianaAges 18 years+ - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Hammond, IndianaAges 18 years+
Hear when a new Liver Diseases trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Liver Diseases trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting liver diseases studies listed above.
- University of Chicago · 7 studies
- Northwestern University · 4 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 3 studies
- Northwestern Memorial Hospital · 3 studies
- ASHA Clinical Research · 2 studies
- Rush University Medical Center · 2 studies
- 89bio Clinical Study Site
What taking part in a liver diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting liver diseases studies in Illinois.
Common questions
- Are there liver diseases clinical trials near Chicago?
- Yes. We're currently tracking 21 recruiting liver diseases studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a liver diseases study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a liver diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New liver diseases studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.